AbbVie Exceeds FY26 Adj. EPS, Q4 Results Top Estimates: ABBV

[Para 1: The Lead] AbbVie Inc. (NYSE: ABBV) has guided fiscal year 2026 adjusted earnings per share (EPS) above market estimates, with fourth quarter (Q4) results surpassing forecasts. The pharmaceutical giant reported Q4 earnings of $2.55 per share, 10% higher than the consensus estimate of $2.31, bolstering confidence in its growth trajectory. [Para 2-3: Supporting details & Context] The company's revenue for the quarter was $10.3 billion, a 4% increase from the same period last year, driven by strong performance in its immunology and virology segments. Full-year 2026 adjusted EPS is now forecasted at $10.70 to $10.90, exceeding the prior guidance of $10.50 to $10.70. AbbVie's strategic focus on R&D and market share expansion continues to yield positive financial outcomes, positioning it as a leader in the pharmaceutical sector.